Loading clinical trials...

Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection

Vitamin D Supplementation and Covid-19: a Randomised, Double- Blind, Controlled Study

NCT04636086•University of Liege

Summary

The objective of the study is to evaluate the clinical efficacy and safety of vitamin D supplementation in hospitalized patients with COVID-19.

Detailed Description

Phase IV, interventional, randomised, double blind, placebo-controlled and parallel study to evaluate the clinical efficacy and safety of vitamin D supplementation in hospitalized patients with COVID-19. Patients will participate in the study for a maximum of 9 weeks, which includes an up to 6-week treatment period and a maximum of 3-week follow-up period. A total of 100 (50 in each group) patients will be randomized in the study and will either receive the test treatment or the placebo treatment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and female over 18 years old (18 years inclusive).
•Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen as diagnosed within 72 hours prior to randomization.
•Expected to survive for at least 96 hours after study entry.
•If patient is a female of childbearing potential, patient must use an effective means of birth control (oral, intravaginal or transdermal oestrogen-progestogen combined hormonal contraceptives or intrauterine devices or sexual abstinence).
•Subject or legally authorized representative understands and agrees to comply with planned study procedures.
•Subject or legally authorized representative provides informed consent prior to initiation of any study procedures.

Exclusion Criteria

•Women currently pregnant or breast-feeding.
•Patients presenting acute impairment of renal function or nephrolithiasis.
•Patients presenting hypercalcaemia and/or hypercalciuria
•Patients presenting pseudohypoparathyroidism
•Use of any vitamin D supplementation alone or in association at screening visit;
•Use of any prohibited medication as detailed in the concomitant medication section
•Patients with any sensitivity or allergy to any of the products used within this clinical trial.
•Presence of any other condition or illness, which, in the opinion of the investigator, would interfere with optimal participation in the study.

Locations (1)

CHU Liège

Liège, Belgium

Key Dates

Start Date

November 12, 2020

Primary Completion Date

April 10, 2022

Completion Date

May 15, 2022

Last Updated

May 19, 2022

Enrollment

ACTUAL participants

Conditions

Covid19

Interventions

Cholecalciferol

DRUG

Placebo

OTHER

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 19, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy